Publications

Oncology

1. Hellstrand K, Hermodsson S.
   Histamine H2-receptor-mediated regulation of human natural killer cell activity. J Immunol 1986; 137:656-660.
2. Hellstrand K, Hermodsson S.
   Synergistic activation of human natural killer cells cytotoxicity by histamine and interleukin-2. Int Arch Allergy Appl Immunol 1990; 92:379-389.
3. Brune M, Hellstrand K.
   Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia. Br J Haematol 1996; 92:620-626.
4. Brune M, Hansson M, Mellqvist UH, Hermodsson S, Hellstrand K.
   NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur J Haematol 1996; 57:312-319.
5. Asea A, Hermodsson S, Hellstrand K.
   Histaminergic regulation of natural killer cell-mediated clearance of tumour cells in mice. Scand J Immunol 1996; 43:9-15.
6. Hellstrand K, Mellquist UH, Wallhult E, Carneskog J, Kimby E, Celsing F, et al.
   Histamine and interleukin-2 in acute myelogenous leukemia. Leuk Lymphoma 1997; 27:429-438.
7. Mellqvist UH, Hansson M, Brune M, Dahlgren C, Hermodsson S, Hellstrand K.
   Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cell: role of reactive oxygen species and regulation by histamine. Blood 2000; 96:1961-1968.
8. Hellstrand K.
   Histamine in cancer immunotherapy: a preclinical background. Semin Oncol 2002; 29(3 Suppl 7):35-40.
9. Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK, et al.
   Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 2006; 108:88-96.
10. Yang W, Guastella J, Huang J, Wang Y, Drewe J, Xue D, et al.
    MX1013, A Dipeptide Caspase Inhibitor with Potent In Vivo Anti-Apoptotic Activity. Br J Pharmacology 2003; 140:402-412.
11. Kasibhatla S, Tseng B.
    Why Target Apoptosis in Cancer Treatment? Mol. Cancer Therap 2003; 2:573-580.
12. Kasibhatla S, Gordeau H, Meerovitch K, Drewe J, Reddy S, Qiu L, et al.
    Discovery and Mechanism of Action of a Novel Series of Apoptosis Inducers with Potent Vascular Targeting Activity. Mol Cancer Therap 2004; 3:1365-1373.
13. Gordeau H, Leblond L, Hamelin B, Desputeau C, Dong K, Kianicka I, et al.
    Antivascular and Antitumor Evaluation of 2-Amino-4-(3-Bromo-4,5-Dimethoxyphenyl )-3-Cyano-4H-Chromenes, a Novel Series of Anti-cancer Agents. Mol Cancer Therap 2004; 3:1375-1383.
14. Kemnitzer W, Kasibhatla S, Jiang S, Zhang H, Wang Y, Zhao J, et al.
    Discovery of 4-Aryl-4H-chromenes as a New Series of Apoptosis Inducers Using a Cell- and Caspase-based High Throughput Screening Assay. 1. Structure-Activity Relationships of the 4-Aryl Group. J Med Chem 2004; 47:6299-6310.
15. Zhang HZ, Drewe J, Herich J, Wang Y, Guastella J, Tseng B, et al.
    Discovery, Characterization and SAR of Gambogic Acid as A Potent Apoptosis Inducer by a HTS Assay. Bioorg Med Chem 2004; 12:309-317.
16. Jessen KA, English NM, Wang JY, Maliartchouk S, Archer SP, Qiu L, et al.
    The discovery and mechanism of action of novel tumor-selective and apoptosis-inducing 3,5-diaryl-1,2,4-oxadiazole series using a chemical genetics approach. Mol Cancer Therap 2005; 4:761-771.
17. Kasibhatla S, Jessen KA, Maliartchouk S, Wang JY, English NM, Drewe J, et al.
    A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc Nat Acad Sci, USA 2005; 102:12095-12100.
18. Cai, SX, Drewe J, Kasibhatla S.
    A chemical genetics approach for the discovery of apoptosis inducers: from phenotypic cell based HTS assay and structure-activity relationship studies, to identification of potential anticancer agents and molecular targets. Curr Med Chem 2006; 13:2627-2644.

Pain Management

1. Sawynok J, Esser MJ, Reid AR.
   Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat. Pain 82 (1999) 149-158.
2. Sawynok J, Reid AR, Esser MJ.
   Peripheral antinociceptive action of amitriptyline in the rat formalin test: involvement of adenosine. Pain 1999 Mar;80 (1-2):45-55.
3. Kolesnikov Yuri A, Chereshnev Igor, Pasternak Gavril W.
   Analgesic Synergy between Topical Lidocaine and Topical Opioids. Journal of Pharmacology and Experimental Therapeutics Vol.295, No.2
4. Kolesnikov Yuri, Pasternak Gavril W.
   Topical Opioids in Mice: Analgesia and Reversal of Tolerance by a Topical N-Methyl-D-Aspartate Antagonist. Journal of Pharmacology and Experimental Therapeutics Vol. 290, No.1.
5. Stein Christoph, Yassouridis Alexander
   Peripheral morphine analgesia. Pain 71 (1997) 119-121.
6. Stein A, Yassouridis A, Szopko C, Helmke K, Stein C.
   Pain 1999 ; 83 : 525-532 Intraarticular morphine versus dexamethasone in chronic arthritis.
7. Likar R, Sittl R, Gragger K, Pipam W, Blatnig H, Breschan C,Schalk HV, Stein C, Schäfer M.
   Pain 1998 ; 76 : 145-150 Peripheral morphine analgesia dental surgery.
8. Freitag F, Diamond S, Lockhart E, Diamond Headache Clinic, EpiCept Corporation
   ASCPT, Orlando, Fla. March 2001, PI-3 Topical Lidocaine in Migraine.
9. Lynch ME, Clark AJ, Sawynok J
   Abstract Canadian Pain Society, Montreal, May 2001; Topical Treatment of Neuropathic Pain, A Double Blind Placebo Controlled Pilot Study Examining the Efficacy of Topical Amitriptyline, Ketamine, and a Combination in the Treatment of Neuropathic Pain.
10. Likar R, Koppert W, Blatnig H, Chiari F, Sittl R, Stein C, Schäfer M.
    Efficacy of Peripheral Morphine Analgesia in Inflamed, Non-Inflamed, and Perineural Tissue of Dental Surgery Patients. Journal of Pain and Symptom Management, April 2001, Vol.21, No.4.
11. Lockhart, E.
    Topical Combination of Amitriptyline and Ketamine for Post Herpetic Neuralgia. The Journal of Pain, Volume 5, Issue 3, Supplement 1, Page S82, April 2004
12. Lockhart, E.
    Topical Combination of Amitriptyline and Ketamine for Post Herpetic Neuralgia. Abstract: Annual Meeting Treatment of Neuropathic Pain, 2004
13. Wiedemann, O. Fenzl. E., Lockhart E. A.
    Topical Sterile Lidocaine Patch to Reduce Postoperative Pain and Decrease Need for Oral analgesics after Inguinal Herniorrhaphy. Submitted to the 11th World Congress of Pain, August 2005